Table 4.
Summary of position of lenvatinib in current international guidelines
| Guideline | Position of lenvatinib |
|---|---|
| NCCN11 (2023) | Recommended regimen as first-line systemic therapy in Child-Pugh Class A advanced HCC patients (with Atezo-Bev and durvalumab plus tremelimumab as preferred regimen) |
| Subsequent line systemic therapy if disease progression | |
| ASCO12 (2020) | First-line treatment for Child-Pugh class A and ECOG PS 0-1 patients with advanced HCC where there are contraindication to Atezo-Bev |
| Second line therapy following first-line treatment with Atezo-Bev | |
| ESMO13 (2021) | First-line systemic option in advanced HCC (while Atezo-Bev regarded as standard) |
| Second-line systemic option with progression after Atezo-Bev | |
| EASL14 (2021) | First-line systemic treatment for advanced HCC with contraindication to Atezo-Bev |
| Second-line systemic therapy after progression of Atezo-Bev | |
| KLCA-NCC15 (2022) | Recommended as first-line systemic therapy for Child-Pugh Class A ECOG PS 0-1 patients with advanced HCC who are unsuitable for Atezo-Bev and durvalumab plus tremelimumab |
| Considered as second-line systemic therapy after failure with Atezo-Bev or durvalumab plus tremelimumab |
NCCN, National Comprehensive Cancer Network; ASCO, American Society of Clinical Oncology; ESMO, European Society for Medical Oncology; EASL, European Association for the Study of the Liver; KLCA-NCC, Korean Liver Cancer Association-National Cancer Center; HCC, hepatocellular carcinoma; Atezo-Bev, atezolizumab and bevacizumab; ECOG, Eastern Cooperative Oncology Group; PS, performance status.